Overview
Brookdale Q2 Adjusted EBITDA rises 19.7%, beating analyst expectations, per LSEG data
Company raises annual guidance for RevPAR and Adjusted EBITDA
Net loss widens to $43 mln due to higher operating expenses
Outlook
Brookdale raises full-year 2025 RevPAR growth guidance to 5.25%-6.00%
Company increases 2025 Adjusted EBITDA guidance to $445 mln-$455 mln
Brookdale expects positive Adjusted Free Cash Flow of $30 mln-$50 mln for 2025
Result Drivers
OCCUPANCY INCREASE - Weighted average occupancy rose to 80.1%, driving higher resident fees
EXPENSES - Facility operating expenses increased due to higher wage rates and maintenance costs
RESTRUCTURING COSTS - General and administrative expenses rose due to transaction and restructuring costs
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income | -$43 mln | ||
Q2 Adjusted EBITDA | Beat | $117.10 mln | $115.20 mln (5 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for Brookdale Senior Living Inc is $7.75, about 1.7% below its August 5 closing price of $7.88
Press Release: ID:nPnb830Rja
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。